Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

A Prospective Randomised Open Label Clinical Trial to Determine the Efficacy of Nevirapine, Compared With a Combination of ZDV + 3TC, in Decreasing the Peripartum Mother to Child Transmission of HIV. Women, Who Present After 38 Weeks Gestation or in Labour After 35 Weeks Gestation and Who Are Anti-retroviral Naive, Will be Included.

The primary objective of the study was to evaluate the efficacy of nevirapine versus ZDV+3TC (Zidovudine + Lamivudine), when administered in labor and again at postdelivery, in reducing peripartum mother to child transmission of HIV (Human Immunodeficiency Virus).

The secondary objective was to assess the overall HIV transmission rate between the 2 groups (intrauterine, intrapartum and postpartum up to 6 weeks) as well as to explore the relationship between infection and timing of maternal dose relative to birth, infant feeding method, maternal peripheral blood viral load, and other potential risk factors for transmission.

Following the introduction of the second and third Amendments to the Protocol, 2 substudies were added. The objectives of these substudies were to evaluate the frequency of resistance-conferring mutations to nevirapine (Amendment 2) and to ZDV+3TC (Amendment 3); to determine whether there was a reversion of any resistant virus to the wild type; and to determine if the resistant virus was transmitted from the mother to the child.

Study Overview

• Status: Completed
• Conditions: HIV Infections
• Intervention / Treatment: Drug: Nevirapine; Drug: Zidovudine (ZDV); Drug: Lamivudine (3TC)

• Study Type: Interventional
• Enrollment (Actual): 2648
• Phase: Phase 3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Pregnant women who present after 38 weeks gestation or in labour after 35 weeks gestation who are tested HIV positive. Estimated gestational age will be determined by one or more of the following:

  • Reliable menstrual history, which corresponds with uterine size
  • Physical examination
  • Estimated fetal weight
• A consent form for the mother and neonate will be signed by either the mother or the guardian prior to inclusion

Exclusion Criteria:

• Mothers who have taken any antiretrovirals in the last 12 months
• Mothers who are not able to take oral medication
• Mothers who present with ARDS (acute respiratory distress syndrome), septic shock or eclampsia
• Mothers presenting in discomfort, i.e. regular painful uterine contractions, or other factors that may contribute to her not being able to understand and sign the informed consent for HIV testing and study participation
• Use of another investigational drug or concurrent participation in another investigational protocol during the current pregnancy
• Unwillingness or inability to reasonably comply with the protocol (i.e., mother and neonate/infant could not be followed for the full 6 weeks of the trial)
• Grade 4 SGPT (Serum glutamate pyruvate transaminase) (>10 times the upper limit of normal value), if known prior to delivery
• A recent history (6 months preceding the study) or current evidence of drug abuse and/or alcoholism
• Mothers with fetuses with anomalies incompatible with life, if known prior to delivery
• Decision to deliver the infant by elective Cesarean section
• Amniocentesis was indicated
• Infants with severe growth retardation diagnosed before birth

Infants who fall into the following groups will not receive treatment, but the mother-infant pair will remain in the trial

• Infants with malformations incompatible with life
• Life-threatening perinatal conditions which do not allow oral therapy (e.g., sepsis)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nevirapine; Mother: two doses, Infant: one dose	Drug: Nevirapine
Active Comparator: Zidovudine (ZDV) + Lamivudine (3TC)	Drug: Zidovudine (ZDV); Drug: Lamivudine (3TC)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of HIV transmission from a HIV positive mother to her exposed infant during the intrapartum and early postpartum period	Day 28, 42 and 56-84

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall HIV transmission rate (including intrauterine, intrapartum and postpartum)	up to 84 days
Time to infection	up to 84 days
Relationship between infection and timing of maternal dose relative to birth	up to 84 days
Relationship between infection and infant feeding method	up to 84 days
Relationship between infection and maternal peripheral blood viral load	Day 0 and 28
Relationship between infection and other potential risk factors	up to 84 days
Number of patients with adverse events	up to 84 days

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start: April 1, 1999
• Primary Completion (Actual): January 1, 2001

Study Registration Dates

• First Submitted: July 2, 2014
• First Submitted That Met QC Criteria: July 2, 2014
• First Posted (Estimate): July 8, 2014

Study Record Updates

• Last Update Posted (Estimate): July 14, 2014
• Last Update Submitted That Met QC Criteria: July 11, 2014
• Last Verified: July 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; HIV Infections; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Antimetabolites; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP3A Inducers; Nevirapine; Lamivudine; Zidovudine
• Other Study ID Numbers: 1100.1287